Artera Gets FDA Okay for Prostate Cancer AI

FDA just signed off on AI predicting long-term cancer outcomes

The ArteraAI prostate test uses artificial intelligence and biomarkers to predict if standard hormone therapy will be effective and for how long.

Artera gets FDA okay for prostate cancer AI

A newly approved AI from Artera can guide treatment and predict prognosis in people diagnosed with localised prostate cancer

FDA grants De Novo authorization for first AI-powered prostate cancer prognostic tool

ArteraAI Prostate advances prostate cancer care with FDA authorization, offering AI-driven insights for personalized treatment and improved diagnostic efficiency.

FDA Okays AI-Based Prostate Cancer Risk-Stratification Tool

The FDA’s De Novo authorization for the tool establishes a new product code category for future AI-powered digital pathology risk-stratification tools.

FDA grants de novo authorisation to Artera’s prostate software

The US Food and Drug Administration (FDA) has granted de novo authorisation to Artera’s ArteraAI Prostate software.The post FDA grants de novo authorisation to Artera’s prostate software appeared first on Medical Device Network.

FDA grants de novo authorization to ArteraAI Prostate

The ArteraAI test is now the first and only AI-powered tool to be authorized to prognosticate long-term outcomes in patients with localized prostate cancer.